Vasa Therapeutics Partners with Eli Lilly's TuneLab AI Platform for CAMKII Inhibitor Development

Key Takeaways

• Vasa Therapeutics partners with Eli Lilly’s TuneLab AI/ML platform to enhance CAMKII delta inhibitor discovery and development
• The collaboration aims to accelerate candidate selection for cardiovascular, neuromuscular, and age-related disorders using predictive AI models
• First-in-human clinical trials are planned for 2027, leveraging extensive crystallography data and AI-driven drug optimization

---

Vasa Therapeutics Announces Strategic AI Partnership with Eli Lilly

ENCINITAS, Calif., April 14, 2026 — Vasa Therapeutics, a clinical-stage biopharmaceutical company, has entered into a strategic partnership with Eli Lilly and Company’s TuneLab AI platform to advance its CAMKII delta inhibitor program. The collaboration will integrate artificial intelligence and machine learning capabilities to accelerate drug discovery for cardiovascular, neuromuscular, and age-related disorders.

AI-Powered Drug Discovery Platform

The partnership combines Vasa’s extensive crystallography database with Lilly TuneLab’s advanced predictive modeling capabilities. This integration is designed to optimize candidate selection and streamline the drug development process for CAMKII (calcium/calmodulin-dependent protein kinase II) delta inhibitors.

CAMKII delta plays a crucial role in cellular signaling pathways associated with heart failure, arrhythmias, and other cardiovascular conditions. By targeting this protein kinase, Vasa aims to develop novel therapeutic approaches for patients with limited treatment options.

Development Timeline and Market Impact

Vasa plans to initiate first-in-human studies by 2027, representing a significant milestone in the company’s development pipeline. The AI-enhanced approach is expected to reduce traditional drug discovery timelines while improving the probability of clinical success.

The pharmaceutical industry has increasingly embraced AI and machine learning technologies to address rising development costs and lengthy approval processes. This partnership exemplifies the growing trend of biotech companies leveraging big pharma’s technological resources to advance innovative therapies.

Therapeutic Applications

The CAMKII inhibitor platform targets multiple therapeutic areas including:

• Cardiovascular disorders: Heart failure, cardiac arrhythmias, and ischemic heart disease
• Neuromuscular conditions: Muscular dystrophy and related muscle-wasting disorders
• Age-related diseases: Conditions associated with cellular aging and metabolic dysfunction

This broad therapeutic potential positions the partnership to address significant unmet medical needs across multiple patient populations.

---

Frequently Asked Questions

What does this partnership mean for patients with cardiovascular disease?

The partnership could accelerate the development of new CAMKII inhibitor treatments for heart failure and arrhythmias, potentially offering patients more effective therapeutic options by 2027 when human trials begin.

When will CAMKII inhibitor treatments be available to patients?

First-in-human trials are planned for 2027. If successful, the treatment could potentially reach patients in the early 2030s, pending regulatory approval and completion of clinical development phases.

How does AI improve drug discovery compared to traditional methods?

AI and machine learning can analyze vast datasets to predict drug behavior, optimize molecular structures, and identify promising candidates faster than traditional methods, potentially reducing development time and improving success rates.